Related Experiment Video

Updated: Apr 17, 2026

Probiotic Studies in Neonatal Mice Using Gavage
10:36

Probiotic Studies in Neonatal Mice Using Gavage

Published on: January 27, 2019

21.3K

[Probiotics for the treatment of infant colic: a clinical case]

Jimena Pérez-Moreno1, Luz Taboada Castro2, Mar Tolín Hernani3

  • 1Sección Gastroenterología y Nutrición Infantil. Hospital General Universitario Gregorio Marañón Madrid.. jimenapermor@gmail.com.

Nutricion Hospitalaria
|February 7, 2015
PubMed

Insights

Infant colic, a common issue in babies, may be linked to gut bacteria imbalances. The probiotic strain L. reuteri DSM 17938 shows promise for treatment with no significant side effects.

Area of Science:

  • Pediatrics
  • Gastroenterology
  • Microbiology

Background:

  • Infant colic affects healthy infants under 3 months, causing distress.
  • Its exact cause is unknown but is considered multifactorial, involving gut microbiota.
  • While typically benign, colic can necessitate therapeutic interventions.

Purpose of the Study:

  • To explore the role of gut microbiota in infant colic.
  • To evaluate the efficacy of probiotic L. reuteri DSM 17938 in managing infant colic.

Main Methods:

  • Review of existing studies on infant colic and gut microbiota.
  • Analysis of the impact of L. reuteri DSM 17938 on colic symptoms.

Main Results:

  • Infant colic is associated with reduced levels of beneficial bacteria like Bifidobacteria and Lactobacilli.
  • An increased presence of bacteria such as Escherichia, Klebsiella, and Pseudomonas is observed.
  • L. reuteri DSM 17938, at 10⁸ CFU/day, demonstrates significant scientific evidence for treating infant colic.

Conclusions:

  • Gut microbiota composition is significantly altered in infants with colic.
  • Probiotic L. reuteri DSM 17938 is a promising therapeutic option for infant colic.
  • L. reuteri DSM 17938 is safe and effective for managing infant colic symptoms.

More Related Videos

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation08:34

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

1.4K
Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

27.9K

Related Concept Videos

Probiotics01:22

Probiotics

Probiotics are live, non-pathogenic microorganisms that confer health benefits by modulating the gut microbiota. The human gastrointestinal tract harbors a complex microbial ecosystem, and the balance of this microbiota is crucial for digestive and systemic health. Among the most extensively studied and utilized probiotics are species formerly classified within the genera Lactobacillus and Bifidobacterium. These organisms not only naturally colonize the human gut but are also consumed through...
240
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
1.1K
Development of Human Microbiota01:30

Development of Human Microbiota

The human microbiota begins developing at birth and undergoes continual change as we age. Infancy marks a critical period of microbial sensitivity, offering a “window of opportunity” during which beneficial microbes help mature the immune system. By age three, children typically develop a more stable and diverse microbial community. Newborns acquire microbes from their immediate environment; vaginal delivery favors maternal vaginal microbes, while cesarean births favor microbes from...
50
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation01:30

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
1.1K
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
950
Irritable Bowel Syndrome I: Introduction01:17

Irritable Bowel Syndrome I: Introduction

Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
1.4K